BioSpace News Archive

CytomX Therapeutics, Inc. (Nasdaq: CTMX), a leader in the field of conditionally activated oncology therapeutics, today announced that it will report fourth quarter and full year 2021 financial results on Tuesday, March 1, 2022, after the close of U.S. markets.

Mersana Therapeutics, Inc. (NASDAQ:MRSN), today announced that it will host a conference call and webcast on Monday, February 28, 2022 at 8:00 a.m. ET to report financial results for the fourth quarter and year ended December 31, 2021 and provide business updates.

Black Diamond Therapeutics, Inc. today announced the appointment of Elizabeth Montgomery as its first Chief People Officer.

Triphase Accelerator, a private drug development company dedicated to advancing novel compounds through clinical proof-of-concept, today announced updated results from its Phase 1 multi-center, open-label, monotherapy study of TRPH-222 in heavily pre-treated patients with relapsed and/or refractory (R/R) B-cell non-Hodgkin’s lymphoma (NHL).

LifeMD, Inc. today announced that it will report its financial results for the year ended December 31, 2021 after the market close on Monday, March 7, 2022.

Aquestive Therapeutics, Inc. announced today that it will report results for fourth quarter and year ended December 31, 2021 and provide an update on recent developments in its business after market close on Tuesday, March 8, 2022.

Kiniksa Pharmaceuticals, Ltd. and Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd. today announced a strategic collaboration to develop and commercialize Kiniksa’s ARCALYST® and mavrilimumab in the Asia Pacific Region.

Enlivex Therapeutics Ltd., a clinical-stage macrophage reprogramming immunotherapy company, announced that Einat Galamidi, M.D. has joined its executive management team as Vice President, Medical.

Armata Pharmaceuticals, Inc. (NYSE American: ARMP) (“Armata” or the “Company”), today announced that the U.S. Food and Drug Administration (“FDA”) has cleared Armata’s Investigational New Drug (IND) application to initiate a clinical trial of its optimized lead therapeutic candidate, AP-PA02, in a second indication, non-cystic fibrosis bronchiectasis (“NCFB”).

Avenge Bio, Inc. announced the appointment of Douglas Carlson as its Chief Operating and Financial Officer.